WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2004096133) METHOD FOR INHIBITING CELLULAR ACTIVATION BY INSULIN-LIKE GROWTH FACTOR-1
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/096133    International Application No.:    PCT/US2004/012231
Publication Date: 11.11.2004 International Filing Date: 21.04.2004
IPC:
A61K 38/17 (2006.01)
Applicants: UNIVERSITY OF NORTH CAROLINA AT CHAPER HILL [US/US]; 308 Bynum Hall, Campus Box 4105, Chapel Hill, NC 27599-4105 (US) (For All Designated States Except US).
CLEMMONS, David, R. [US/US]; (US) (For US Only).
MAILE, Laura, A. [GB/US]; (US) (For US Only)
Inventors: CLEMMONS, David, R.; (US).
MAILE, Laura, A.; (US)
Agent: MYERS BIGEL SIBLEY & SAJOVEC, P.A.; P.O. Box 37428, Raleigh, NC 27627 (US)
Priority Data:
10/422,588 24.04.2003 US
Title (EN) METHOD FOR INHIBITING CELLULAR ACTIVATION BY INSULIN-LIKE GROWTH FACTOR-1
(FR) METHODE D'INHIBITION DE L'ACTIVATION CELLULAIRE AU MOYEN DU FACTEUR DE CROISSANCE 1 ANALOGUE A L'INSULINE
Abstract: front page image
(EN)A method of inhibiting cellular activation by Insulin-like Growth Factor-I (IGF-1) in a subject in need thereof (e.g., a subject afflicted with cancer, atherosclerosis or other disease) comprises administering an antagonist that inhibits the binding of IAP to SHPS-l to the subject in an amount effective to inhibit cellular activation by IGF-1. Compounds and compositions for carrying out such methods are also described.
(FR)L'invention concerne une méthode permettant d'inhiber l'activation cellulaire au moyen du facteur de croissance 1 analogue à l'insuline (IGF-1) chez un sujet qui en a besoin (un sujet souffrant de cancer, d'athérosclérose ou d'une autre maladie, par exemple). La méthode selon l'invention consiste à administrer au sujet un antagoniste qui inhibe la liaison de IAP à SHPS-1, en une quantité efficace pour inhiber l'activation cellulaire au moyen de l'IGF-1. L'invention concerne également des composés et des compositions destinés à mettre en oeuvre ces méthodes.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)